JNCE - Jounce Therapeutics, Inc.
| Previous Close | 3.5200 |
| Open | 3.5100 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1100 |
| Day's Range | 3.4000 - 3.6500 |
| 52 Week Range | 2.6600 - 7.3500 |
| Volume | 546,650 |
| Avg. Volume | 167,840 |
| Market Cap | 116.425M |
| Beta (3Y Monthly) | 3.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8850 |
| Earnings Date | Aug 10, 2018 - Aug 11, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
- Simply Wall St.
Introducing Jounce Therapeutics (NASDAQ:JNCE), The Stock That Dropped 35% In The Last Year
The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...
- GlobeNewswire
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
CAMBRIDGE, Mass., Oct. 01, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- GlobeNewswire
Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jacqui Fahey Sandell has been appointed as chief legal officer and corporate secretary. Jacqui brings over 20 years of experience in the biotechnology and pharmaceutical industry, as well as in private practice. Most recently, she served as vice president, general counsel and corporate secretary at Vericel Corporation, where she was responsible for all legal matters and supported the launch and commercialization of MACI®.
- Thomson Reuters StreetEvents
Edited Transcript of JNCE.O earnings conference call or presentation 7-Aug-19 12:00pm GMT
Q2 2019 Jounce Therapeutics Inc Earnings Call
- GlobeNewswire
Jounce Therapeutics to Present at Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Aug. 28, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- Simply Wall St.
Do Institutions Own Shares In Jounce Therapeutics, Inc. (NASDAQ:JNCE)?
A look at the shareholders of Jounce Therapeutics, Inc. (NASDAQ:JNCE) can tell us which group is most powerful...
- Zacks
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing.
- GlobeNewswire
Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2019 financial results and provide a corporate update before market open on Wednesday, August 7, 2019. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET. Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients.
- Benzinga
What To Know About Jounce's Amended Licensing Deal With Celgene
Jounce Therapeutics Inc (NASDAQ: JNCE ) shares are trading higher after the company announced an amended licensing agreement with Celgene Corporation (NASDAQ: CELG ), the latter of which has agreed to ...
- Zacks
Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
Key highlights of the past week include earnings update, collaborations and other pipeline news.
- Benzinga
The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 23) Akero Therapeutics Inc (NASDAQ: AKRO ) Mirum Pharmaceuticals ...
- GlobeNewswire
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced an update on its strategic collaboration with Celgene Corporation (CELG), originally established in July 2016. Under the terms of a new license agreement, Celgene has licensed worldwide rights to JTX-8064, a highly-selective, potential first-in-class antibody that targets the LILRB2 receptor on macrophages.
- Thomson Reuters StreetEvents
Edited Transcript of JNCE.O earnings conference call or presentation 8-May-19 12:00pm GMT
Q1 2019 Jounce Therapeutics Inc Earnings Call
- Insider Monkey
Is Jounce Therapeutics, Inc. (JNCE) A Good Stock To Buy?
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of March 31. The results of that effort will be put on display in this article, as […]
- GlobeNewswire
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has initiated dosing in the Phase 2 EMERGE clinical trial of its lead product candidate, vopratelimab, in combination with ipilimumab in patients with non-small cell lung cancer (NSCLC) or urothelial cancer who have progressed on or after PD-1/PD-L1 inhibitor therapies. “The Phase 2 EMERGE clinical trial of vopratelimab and ipilimumab builds upon the original science from our founders as well as the reverse translational subset analysis from patients who benefitted in our ICONIC trial versus those who did not.
- GlobeNewswire
Jounce Therapeutics to Present at Upcoming Investor Conferences in June
CAMBRIDGE, Mass., June 11, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- Simply Wall St.
Estimating The Intrinsic Value Of Jounce Therapeutics, Inc. (NASDAQ:JNCE)
Does the May share price for Jounce Therapeutics, Inc. (NASDAQ:JNCE) reflect what it's really worth? Today, we will...
- Zacks
Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -22.58% and -25.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Jounce Therapeutics Reports First Quarter 2019 Financial Results
- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in.
- Zacks
Will Jounce Therapeutics, Inc. (JNCE) Report Negative Q1 Earnings? What You Should Know
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2019 financial results and provide a corporate update before market open on Wednesday, May 8, 2019. Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET. Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients.
- Motley Fool
Here's Why Jounce Therapeutics Rose 39.3% in March
The biopharma announced full-year 2018 operating results.
- GlobeNewswire
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., April 03, 2019 -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies.
- GlobeNewswire
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported new clinical data on vopratelimab (JTX-2011) at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA. The Jounce poster presentations show that patients in the ICONIC trial with emergence of ICOS hi CD4 T cells have improved progression free survival (PFS) and overall survival (OS) compared to patients with ICOS lo CD4 T cells.
